FGFR1OP2

Summary

FGFR1OP2 (FGFR1 oncogene partner 2, HGNC:23098) is a protein-coding gene on chromosome 12p11.23, encoding FGFR1 oncogene partner 2 (Q9NVK5). May be involved in wound healing pathway. It is a selective cancer dependency (DepMap: 14.8% of cell lines).

Predicted to enable identical protein binding activity. Predicted to be involved in response to wounding. Predicted to act upstream of or within wound healing. Predicted to be located in cytosol.

Source: NCBI Gene 26127 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 34 total
• Cancer dependency (DepMap): dependent in 14.8% of screened cell lines
• MANE Select transcript: NM_015633

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23098
Approved symbol	FGFR1OP2
Name	FGFR1 oncogene partner 2
Location	12p11.23
Locus type	gene with protein product
Status	Approved
Aliases	DKFZp564O1863
Ensembl gene	ENSG00000111790
Ensembl biotype	protein_coding
OMIM	608858
Entrez	26127

Gene structure

Transcript identifiers

Ensembl transcripts: 18 — 16 protein_coding, 2 retained_intron

ENST00000229395, ENST00000327214, ENST00000395941, ENST00000538172, ENST00000544111, ENST00000546072, ENST00000887799, ENST00000887800, ENST00000887801, ENST00000887802, ENST00000887803, ENST00000887804, ENST00000915792, ENST00000972030, ENST00000972031, ENST00000972032, ENST00000972033, ENST00000972034

RefSeq mRNA: 3 — MANE Select: NM_015633 NM_001171887, NM_001171888, NM_015633

CCDS: CCDS53766, CCDS53767, CCDS8709

Canonical transcript exons

ENST00000229395 — 7 exons

Exon	Start	End
ENSE00000732709	26960515	26960628
ENSE00000936587	26957601	26957743
ENSE00001189198	26964596	26966648
ENSE00001346961	26963342	26963455
ENSE00001346990	26938470	26938710
ENSE00003510128	26954145	26954293
ENSE00003521909	26956543	26956660

Expression profiles

Bgee: expression breadth ubiquitous, 262 present calls, max score 96.62.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 37.2315 / max 566.8922, expressed in 1815 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
124822	18.4727	1795
124823	15.6481	1775
124821	2.0986	902
124825	0.6830	341
124824	0.3143	130
124826	0.0148	7

Top tissues by expression

262 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	96.62	gold quality
monocyte	CL:0000576	96.00	gold quality
left ovary	UBERON:0002119	95.99	gold quality
leukocyte	CL:0000738	95.74	gold quality
right ovary	UBERON:0002118	95.41	gold quality
secondary oocyte	CL:0000655	95.33	gold quality
corpus callosum	UBERON:0002336	95.21	gold quality
Brodmann (1909) area 9	UBERON:0013540	95.11	gold quality
lymph node	UBERON:0000029	94.91	gold quality
ovary	UBERON:0000992	94.69	gold quality
oocyte	CL:0000023	94.62	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	94.62	gold quality
epithelial cell of pancreas	CL:0000083	94.44	gold quality
spinal cord	UBERON:0002240	94.30	gold quality
left adrenal gland	UBERON:0001234	94.10	gold quality
vermiform appendix	UBERON:0001154	94.01	gold quality
cardiac muscle of right atrium	UBERON:0003379	93.96	gold quality
bone marrow	UBERON:0002371	93.94	gold quality
right adrenal gland	UBERON:0001233	93.91	gold quality
tibial nerve	UBERON:0001323	93.90	gold quality
left adrenal gland cortex	UBERON:0035825	93.90	gold quality
tendon	UBERON:0000043	93.76	gold quality
gall bladder	UBERON:0002110	93.71	gold quality
adrenal cortex	UBERON:0001235	93.68	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	93.67	gold quality
smooth muscle tissue	UBERON:0001135	93.66	gold quality
thymus	UBERON:0002370	93.59	gold quality
adrenal gland	UBERON:0002369	93.56	gold quality
superior frontal gyrus	UBERON:0002661	93.53	gold quality
right adrenal gland cortex	UBERON:0035827	93.45	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-9221	yes	12.22
E-MTAB-11011	no	225.00
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

154 targeting FGFR1OP2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548J-5P	99.94	71.14	3489
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 14.8% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 4)

• FGFR1OP2 is a new FGFR1 fusion gene involving a chromosomes 12X8 translocation in a 8p11 myeloproliferative syndrome patient. (PMID:15034873)
• FGFR1OP2/wit3.0 may regulate cell motility and stimulate wound closure. (PMID:19959814)
• patients with the minor allele of rs840869 or rs859024 of FGFR1OP2 were associated with excessive atrophy of edentulous mandible (PMID:21283824)
• The patient with minor allele of ss518063493 may be associated with excessive atrophy of edentulous mandible whereas the patients with that of rs840869 are not associated in Korean population. (PMID:22880093)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	fgfr1op2	ENSDARG00000009657
mus_musculus	Fgfr1op2	ENSMUSG00000040242
rattus_norvegicus	Fgfr1op2	ENSRNOG00000001811
drosophila_melanogaster	Fgop2	FBGN0031871
caenorhabditis_elegans		WBGENE00007579

Paralogs (1): SIKE1 (ENSG00000052723)

Protein

Protein identifiers

FGFR1 oncogene partner 2 — Q9NVK5 (reviewed: Q9NVK5)

All UniProt accessions (2): Q9NVK5, F5GX47

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in wound healing pathway.

Subcellular location. Cytoplasm.

Tissue specificity. Expressed in bone marrow, spleen and thymus.

Disease relevance. A chromosomal aberration involving FGFR1OP2 may be a cause of stem cell myeloproliferative disorder (MPD). Insertion ins(12;8)(p11;p11p22) with FGFR1. MPD is characterized by myeloid hyperplasia, eosinophilia and T-cell or B-cell lymphoblastic lymphoma. In general it progresses to acute myeloid leukemia. The fusion protein FGFR1OP2-FGFR1 may exhibit constitutive kinase activity and be responsible for the transforming activity.

Similarity. Belongs to the SIKE family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9NVK5-1	1	yes
Q9NVK5-2	2
Q9NVK5-3	3

RefSeq proteins (3): NP_001165358, NP_001165359, NP_056448* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008555	SIKE	Family

Pfam: PF05769

UniProt features (12 total): splice variant 3, sequence conflict 2, coiled-coil region 2, chain 1, region of interest 1, compositionally biased region 1, site 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NVK5-F1	78.59	0.44

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 132–133 (breakpoint for translocation to form fgfr1op2-fgfr1)

Post-translational modifications (1): 141

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-1839117	Signaling by cytosolic FGFR1 fusion mutants
R-HSA-5655302	Signaling by FGFR1 in disease

MSigDB gene sets: 167 (showing top): RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, GGGTGGRR_PAX4_03, AAAYRNCTG_UNKNOWN, GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLUE_UP, FOXD3_01, chr12p11, GOBP_WOUND_HEALING, MILI_PSEUDOPODIA_HAPTOTAXIS_UP, SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN, PYEON_CANCER_HEAD_AND_NECK_VS_CERVICAL_UP, DODD_NASOPHARYNGEAL_CARCINOMA_UP, AACTTT_UNKNOWN, ATAACCT_MIR154, NRF2_01, ZHANG_BREAST_CANCER_PROGENITORS_UP

GO Biological Process (2): response to wounding (GO:0009611), wound healing (GO:0042060)

GO Molecular Function (2): identical protein binding (GO:0042802), protein binding (GO:0005515)

GO Cellular Component (2): cytosol (GO:0005829), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
FGFR1 mutant receptor activation	1
Signaling by FGFR in disease	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
response to stress	1
response to wounding	1
tissue regeneration	1
protein binding	1
binding	1
cytoplasm	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

674 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FGFR1OP2	ZMYM2	Q9UBW7	870
FGFR1OP2	SLMAP	Q14BN4	842
FGFR1OP2	FGFR1	P11362	818
FGFR1OP2	MYO18A	Q92614	791
FGFR1OP2	CEP43	O95684	781
FGFR1OP2	CTTNBP2NL	Q9P2B4	677
FGFR1OP2	ZNF112	Q9UJU3	641
FGFR1OP2	STRIP1	Q5VSL9	589
FGFR1OP2	TRAF3IP3	Q9Y228	572
FGFR1OP2	MOB4	Q9Y3A3	563
FGFR1OP2	SIKE1	Q9BRV8	554
FGFR1OP2	TRIM24	O15164	531
FGFR1OP2	TM7SF3	Q9NS93	521
FGFR1OP2	STRIP2	Q9ULQ0	514
FGFR1OP2	STRN4	Q9NRL3	483

IntAct

76 interactions, top by confidence:

A	B	Type	Score
PDCD10	STK25	psi-mi:“MI:0914”(association)	0.980
STK25	STRN	psi-mi:“MI:0914”(association)	0.900
STK24	STK25	psi-mi:“MI:0914”(association)	0.890
PPP2R1A	STRN	psi-mi:“MI:0914”(association)	0.880
STRN3	STK25	psi-mi:“MI:0914”(association)	0.880
STRN3	STRN	psi-mi:“MI:0914”(association)	0.880
STRN3	STRN	psi-mi:“MI:2364”(proximity)	0.880
STK24	STRN	psi-mi:“MI:0914”(association)	0.870
STRIP1	PPP2CB	psi-mi:“MI:0914”(association)	0.870
STK26	STRN	psi-mi:“MI:0914”(association)	0.860
STRIP1	STK25	psi-mi:“MI:0914”(association)	0.840
SIKE1	SLMAP	psi-mi:“MI:0914”(association)	0.770
MOB4	STK25	psi-mi:“MI:0914”(association)	0.730
SIKE1	STRN	psi-mi:“MI:0914”(association)	0.730
PSMC5	PSMD11	psi-mi:“MI:0914”(association)	0.730
SLMAP	STRN	psi-mi:“MI:0914”(association)	0.710
SLMAP	STRN	psi-mi:“MI:2364”(proximity)	0.710
STK4	STRN	psi-mi:“MI:0914”(association)	0.610
STK4	STRN	psi-mi:“MI:2364”(proximity)	0.610
HAUS1	FGFR1OP2	psi-mi:“MI:0915”(physical association)	0.560
Strn	PPP2R1A	psi-mi:“MI:2364”(proximity)	0.540

BioGRID (171): HAUS1 (Two-hybrid), FGFR1OP2 (Affinity Capture-MS), FGFR1OP2 (Affinity Capture-MS), FGFR1OP2 (Affinity Capture-MS), FGFR1OP2 (Affinity Capture-MS), FGFR1OP2 (Affinity Capture-MS), CAV1 (Affinity Capture-MS), STOM (Affinity Capture-MS), GANC (Affinity Capture-MS), NDUFS1 (Affinity Capture-MS), PHB (Affinity Capture-MS), PPP2CA (Affinity Capture-MS), PPP2R1A (Affinity Capture-MS), PPP2R1B (Affinity Capture-MS), STRN (Affinity Capture-MS)

ESM2 similar proteins: A1YB07, A4IGC3, A5PJI6, A8NJZ7, B1PRL5, B8AE37, O08970, O35867, O46480, O94876, P57077, P58500, Q0P4J3, Q0V9C8, Q29EP6, Q2KI75, Q2KJD6, Q3E784, Q3SZV2, Q4R4S6, Q5BKX8, Q5ZMC9, Q66J96, Q66JL0, Q69ZZ6, Q6AYB8, Q6DBR9, Q6DDT0, Q6DFB7, Q6GNW0, Q6IP02, Q6K678, Q6P402, Q6SXP0, Q6TA25, Q78PB6, Q8BHS8, Q8CCX5, Q8N6V9, Q8R2X8

Diamond homologs: O02197, Q0VCF3, Q5FWT9, Q5I033, Q5R561, Q5R8J5, Q5ZKJ4, Q6DF11, Q6GP65, Q6TA25, Q7T338, Q8AVR2, Q9BRV8, Q9CPR7, Q9CRA9, Q9NVK5, Q9VM65

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 57 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Degradation of beta-catenin by the destruction complex	7	40.4×	1e-07
Separation of Sister Chromatids	6	12.2×	2e-04

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of hippo signaling	7	106.8×	7e-11
protein autophosphorylation	6	18.9×	7e-05
protein phosphorylation	7	10.3×	3e-04
intracellular signal transduction	10	8.3×	4e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

34 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	27
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1088 predictions. Top by Δscore:

Variant	Effect	Δscore
12:26938599:G:GT	donor_gain	1.0000
12:26938709:GA:G	donor_gain	1.0000
12:26938711:G:GG	donor_gain	1.0000
12:26954143:A:AG	acceptor_gain	1.0000
12:26954144:G:GG	acceptor_gain	1.0000
12:26954144:GAT:G	acceptor_gain	1.0000
12:26954144:GATAT:G	acceptor_gain	1.0000
12:26954273:C:T	donor_gain	1.0000
12:26954292:AGG:A	donor_loss	1.0000
12:26954293:GGTTT:G	donor_loss	1.0000
12:26954294:G:A	donor_loss	1.0000
12:26954295:T:A	donor_loss	1.0000
12:26956538:A:AG	acceptor_gain	1.0000
12:26956539:TTA:T	acceptor_loss	1.0000
12:26956541:A:AG	acceptor_gain	1.0000
12:26956541:A:AT	acceptor_loss	1.0000
12:26956542:G:GT	acceptor_gain	1.0000
12:26956542:GT:G	acceptor_gain	1.0000
12:26956542:GTA:G	acceptor_gain	1.0000
12:26956542:GTAT:G	acceptor_gain	1.0000
12:26956656:CAAAG:C	donor_gain	1.0000
12:26956657:AAAG:A	donor_gain	1.0000
12:26956658:AAG:A	donor_gain	1.0000
12:26956658:AAGGT:A	donor_loss	1.0000
12:26956659:AG:A	donor_gain	1.0000
12:26956659:AGG:A	donor_loss	1.0000
12:26956660:GG:G	donor_gain	1.0000
12:26956661:G:GA	donor_loss	1.0000
12:26956661:G:GG	donor_gain	1.0000
12:26957599:A:AG	acceptor_gain	1.0000

AlphaMissense

1688 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:26957643:T:C	L99P	1.000
12:26954192:G:C	A12P	0.999
12:26954193:C:A	A12D	0.999
12:26954202:T:C	L15P	0.999
12:26954244:T:C	L29P	0.999
12:26957604:T:C	L86S	0.999
12:26957616:T:C	L90P	0.999
12:26957646:T:A	I100K	0.999
12:26957650:G:A	M101I	0.999
12:26957650:G:C	M101I	0.999
12:26957650:G:T	M101I	0.999
12:26957661:G:C	R105P	0.999
12:26963451:T:C	L207P	0.999
12:26964612:T:C	L214S	0.999
12:26954214:T:C	L19S	0.998
12:26954234:G:C	A26P	0.998
12:26956604:T:A	V66D	0.998
12:26956643:T:C	L79S	0.998
12:26956646:A:C	Q80P	0.998
12:26956654:A:G	N83D	0.998
12:26957612:T:C	S89P	0.998
12:26957624:C:G	H93D	0.998
12:26957625:A:C	H93P	0.998
12:26957633:G:C	A96P	0.998
12:26957634:C:A	A96D	0.998
12:26957646:T:G	I100R	0.998
12:26957657:T:G	Y104D	0.998
12:26963396:G:C	A189P	0.998
12:26964624:T:C	L218P	0.998
12:26954231:G:C	A25P	0.997

dbSNP variants (sampled 300 via entrez): RS1000159073 (12:26950336 C>A), RS1000167621 (12:26943192 T>C), RS1000199733 (12:26943463 A>G), RS1000307069 (12:26956747 T>C), RS1000371226 (12:26944987 A>G), RS1000461919 (12:26950477 C>G,T), RS1000539427 (12:26961330 A>G,T), RS1000613441 (12:26955559 A>G), RS1000678752 (12:26956966 T>C), RS1000719707 (12:26938296 C>G,T), RS1000897513 (12:26953360 T>C), RS1001253842 (12:26950312 T>C), RS1001418001 (12:26938426 T>C), RS1001501567 (12:26948548 C>G), RS1001538690 (12:26962656 C>T)

Disease associations

OMIM: gene MIM:608858 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST90002379_99	Basophil count	7.000000e-12
GCST90002380_105	Basophil percentage of white cells	1.000000e-14

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0005090	basophil count
EFO:0007992	basophil percentage of leukocytes

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

42 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases methylation, increases expression, affects expression, decreases expression	4
bisphenol A	increases methylation, decreases reaction, increases abundance, decreases expression, increases expression	3
Acetaminophen	affects expression, increases expression	2
Cyclosporine	increases expression	2
ginger extract	decreases reaction, increases abundance, increases expression	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
trichostatin A	affects expression	1
methylparaben	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	increases expression	1
perfluorooctanoic acid	increases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
monomethylarsonous acid	increases expression	1
perfluorohexanesulfonic acid	decreases expression	1
ICG 001	decreases expression	1
NSC 689534	affects binding, increases expression	1
Bortezomib	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Arsenic Trioxide	increases expression	1
Vorinostat	increases expression	1
Amiodarone	increases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	decreases methylation	1
Copper	affects binding, increases expression	1
Hydrogen Peroxide	decreases expression	1
Lead	affects splicing	1
Methyl Methanesulfonate	decreases expression	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_0374	KG-1	Cancer cell line	Male
CVCL_1824	KG-1a	Cancer cell line	Male
CVCL_5301	KMT-2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.